Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02813746
Other study ID # 1603-IGX-018-CS
Secondary ID
Status Recruiting
Phase N/A
First received June 22, 2016
Last updated June 27, 2016
Start date April 2016
Est. completion date April 2019

Study information

Verified date June 2016
Source Igenomix
Contact Carlos Gomez, BSc MSc
Phone +34963905310
Email carlos.gomez@igenomix.es
Is FDA regulated No
Health authority Spain: Ministry of Health
Study type Observational

Clinical Trial Summary

The aim of this study is to understand the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD), either for the presence of metabolic disorders in the future mothers, such as obesity or for the exposure to certain contaminants such as tobacco.

To do that, the miRNAs profiles secreted to the endometrial fluid in obese women vs normoweight women during the window of implantation will be identified. Likewise, it will be studied how that miRNA signature is normalized once a substantial loss of weight is produced by the patients involved in the studied. In parallel, a comparison of the miRNA expression profiles secreted in the endometrial fluid in smoker women vs nonsmoker women will be performed. As in the previous case, it will be studied if after the exposure to these contaminant, the normalization of the miRNA expression signature occurs. Finally, an in silico analysis will be carried out in order to define the target genes and the metabolic pathways affected by the miRNAs profile secreted in both pathological conditions


Description:

The developmental origins of adult disease are now recognized to be related to intrauterine conditions during embryonic and fetal life. Pregnancy begins with embryo implantation and its impact in adult life remains unknown. It has been demonstrated that human endometrial epithelium secretes specific microRNAs (miRNAs) during the time frame when the embryo enters the uterine cavity and initiates its adhesion to the uterine wall. Maternal miRNAs are secreted to the endometrial fluid, transported through exosomes or bound to proteins and consequently uptaken by the preimplantation embryo, before implantation occurs. As a consequence they suffer transcriptomic modifications that induce profound molecular and functional changes. The data already published demonstrate a novel paradigm: the transcriptomic maternal endometrial regulation of the pre-implantation embryo in health.

Here, this novel maternal endometrium-based mechanism will be applied in order to understand and prevent the developmental origin of adult diseases induced during embryonic implantation either by metabolic disorders of future mothers who have developed obesity or by the exposure to certain contaminants such as tobacco. In this project, the expression profiles of secreted miRNAs will be identified in the endometrial fluid in obese women compared to normo-weight women. Also, it will be studied how this "obese" endometrial miRNA pattern is reversed after weight-loss. In parallel, murine models of obesity will be used to proof this concept. In addition, the expression profiles of secreted endometrial miRNAs will be identified in smokers versus future non-smokers mothers. As in the previous case, the reversion of this signature will be analysed after stopping the exposure to this contaminant.

Then, "in silico" analysis will be done to select putative genes and functional pathways targeted by the signature of secreted endometrial miRNAs in the human and murine models in both pathological conditions. The determination of the transcriptomic and/or epigenome modifications induced by "obese" or/and "smoker" endometrial miRNAs in preimplantation mouse embryos is expected. As preliminary results, to support this project our accepted model of transcriptomic maternal endometrial regulation of the pre-implantation embryo in health, and the identification of a differential pattern of secreted miRNAs in the endometrial fluid of obese women compared to normo-weight counterparts is presented. In consequence, the application of this novel endometrium-based mechanism to the understanding and prevention of the origin of adult diseases related to obesity and/or tobacco exposure is proposed.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date April 2019
Est. primary completion date April 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Women with age comprised between 18 and 45 years

- Normal uterus (evaluated trough ultrasound 2D/3D and/or hysteroscopy)

- Presence of at least one ovary

- Body mass index:

- Normoweight: 18.0-24.9 kg/m2 and non smokers

- Obese =30.0 kg/m2 and non smokers

- Smokers: Normoweight and smoke at least 10 cigarettes per day

Exclusion Criteria:

- Overweight=25.0-29.9 kg/m2

- Patients with Intrauterine device in the last 3 months

- Patients who had had hormonal contraceptives in the 2 previous months.

- Adnexal or uterine pathologies

- Polycystic ovary

- Existence of serious or uncontrolled bacterial, fungal or viral infections that could interfere with the involvement of the patient in the study or in the evaluation of the study results.

- Any disease or medical condition that could be unstable or could endanger the security of the patient and her compliance in the study.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fitness program

Behavioral:
Stop smoking

Procedure:
Endometrial fluid collection


Locations

Country Name City State
Spain IVI Valencia Valencia

Sponsors (1)

Lead Sponsor Collaborator
Igenomix

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Understanding of the epigenetic and transcriptomic mechanisms that regulate the FOAD The main objective of the present project is focused on understanding the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD) either by the presence of metabolic disorders in mothers such as obesity, or by the exposure to certain pollutants such as tobacco 40 months No
Secondary Analysis of the miRNA expression pattern in the endometrial fluid (EF) in obese patients Analysis of the miRNA expression profile in the endometrial fluid miRNA expression profile will be analysed in obese women , in comparison to normoweight women during the window of implantation. In turn, the normalization of this particular transcriptomic signature will be studied after the existence of a substantial loss of weight by the patients involved in the study. 13 months No
Secondary Analysis of the miRNA expression pattern in the endometrial fluid (EF) in smoker patients A comparison between the miRNA expression profiles in smoker women vs. non-smoker will be done in the endometrial fluid (EF) during the window of implantation. As in the previous case, it will be studied if that particular pattern is normalized after giving up smoking. 13 months No
Secondary Functional analysis The target genes and the metabolic routes affected by the miRNA profile secreted in both pathological conditions will be defined. 13 months No